Generic Pravachol
This article was originally published in The Tan Sheet
Executive Summary
FDA approval of Teva's generic pravastatin 10 mg, 20 mg and 40 mg is expected when Bristol-Myers Squibb's Pravachol patent expires April 20, Teva announces April 12. FDA "has denied Apotex's request for an agency determination that 180-day exclusivity for pravastatin 10 mg, 20 mg and 40 mg has been triggered and run," the firm adds. Teva was the first to file an ANDA for pravastatin but said it would not market the generic version until Pravachol's patent expired. However, voluntary dismissal of a complaint by Apotex regarding the drug triggered Teva's 180-day exclusivity period, which then would have expired in February. The firm sued FDA, and a federal appeals court remanded the case to the agency in March (1"The Tan Sheet" March 20, 2006, p. 13). According to Teva, FDA says it "interprets the court decision trigger provision to require a decision of a court that on its face evidences a holding on the merits of patent noninfringement, invalidity, or unenforceability. The July 23, 2004 Apotex-Bristol dismissal does not contain such a holding"...
You may also be interested in...
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.